2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T9e5,The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs). To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs. In this case-time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)-α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024. The initiation of the biologic was screened in both periods. The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator. Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change. In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.31:Tf24, Importance The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs). Objective To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs. Design, Setting, and Participants In this case–time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)–α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024. Exposure The initiation of the biologic was screened in both periods. Main Outcomes and Measures The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator. Results Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk ( P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change. Conclusions In this case–time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"TNF-Alpha Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on TNF-Alpha Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/TNF-Alpha%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"TNF-Alpha Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/TNF-Alpha%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"TNF-Alpha Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: TNF-Alpha Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1093/ced/llag322","pmid":"42487627","title":"Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution","journal_title":"Clinical and Experimental Dermatology","journal_issn":"0307-6938","published_at":"2026-07-23T00:00:00.000Z","url":"https://doi.org/10.1093/ced/llag322","source_score":1,"is_retracted":false,"is_open_access":null,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":false},"created_at":"2026-07-26T13:44:49.302Z","updated_at":"2026-07-26T13:44:49.302Z","tags":[{"paper_doi":"10.1093/ced/llag322","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"condition","value":"Cutaneous Leishmaniasis","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"sample_size","value":"n=20","value_numeric":20},{"paper_doi":"10.1093/ced/llag322","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"warning","value":"Age group inferred as 'adult' based on typical anti-TNF-α prescribing patterns; pediatric cases cannot be excluded.","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"warning","value":"Full text was not available — summary is based solely on the paper title, journal, and metadata. Key results such as specific outcome rates, treatment used, and Leishmania species are not confirmed from source text.","value_numeric":null},{"paper_doi":"10.1093/ced/llag322","tag_type":"warning","value":"Sex of the study population was not reported in the available metadata and has been omitted.","value_numeric":null}],"summaries":{"what_studied":"This single-institution case series examined 20 patients who developed cutaneous leishmaniasis (CL) while receiving anti-TNF-α therapy, evaluating clinical presentation, management, and outcomes in this immunocompromised population.","key_result":"20 cases of CL were identified in patients on anti-TNF-α treatment; specific outcome rates and treatment response numbers are not available from the provided abstract alone.","limitations":"Single-institution retrospective case series with a small sample (n=20), limiting generalizability; no control group for comparison with immunocompetent CL patients.","practice_takeaway":"Clinicians should consider cutaneous leishmaniasis in patients on anti-TNF-α biologics who present with atypical or non-healing skin lesions, particularly in or with travel history to endemic areas. Prompt recognition is key, as immunosuppression may alter the clinical course."}},{"doi":"10.1080/09273948.2026.2696517","pmid":"42367087","title":"Efficacy of infliximab therapy in the treatment of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome","journal_title":"Ocular Immunology and Inflammation","journal_issn":"0927-3948","published_at":"2026-06-29T00:00:00.000Z","url":"https://doi.org/10.1080/09273948.2026.2696517","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-05T13:38:39.224Z","updated_at":"2026-07-05T13:38:39.224Z","tags":[{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"condition","value":"Idiopathic Retinal Vasculitis, Aneurysms, And Neuroretinitis Syndrome","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"condition","value":"Retinal Vasculitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"sample_size","value":"n=3","value_numeric":3},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"warning","value":"Brand name 'Remicade' assigned as the canonical infliximab brand; biosimilar use was not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"warning","value":"Extremely small sample (n=3); findings are hypothesis-generating only and should not guide broad practice changes without larger studies.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696517","tag_type":"warning","value":"One patient was 17 years old; the age_group tag is set to 'adult' reflecting the mean, but the sample spans adolescent to adult — findings may not be uniform across age groups.","value_numeric":null}],"summaries":{"limitations":"Very small sample size (n=3) limits generalizability. No control group or comparator arm. Short mean follow-up of 14 months may not capture late relapses or delayed adverse effects.","practice_takeaway":"Infliximab appears safe and effective for IRVAN syndrome in this small series. Early initiation after diagnosis may help preserve vision and prevent irreversible structural damage.","what_studied":"Prospective case series evaluating systemic infliximab therapy in 3 patients (mean age 32.3 years) with IRVAN syndrome, with multimodal imaging follow-up over a mean of 14 months (range 6–24 months).","key_result":"All 3 patients showed favorable response: regression of retinal and optic nerve head aneurysms, resolution of vascular leakage, resorption of macular exudates, and stable or improved BCVA. No serious systemic adverse events were recorded."}},{"doi":"10.1002/jpn3.70484","pmid":"42299734","title":"Chronic nonbacterial osteomyelitis and inflammatory bowel disease in children: A French national cohort","journal_title":"Journal of Pediatric Gastroenterology and Nutrition","journal_issn":"0277-2116","published_at":"2026-06-16T00:00:00.000Z","url":"https://doi.org/10.1002/jpn3.70484","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-25T13:25:16.556Z","updated_at":"2026-06-25T13:25:16.556Z","tags":[{"paper_doi":"10.1002/jpn3.70484","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"condition","value":"Chronic Nonbacterial Osteomyelitis","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"generic","value":"anti-TNF-alpha antibodies","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"sample_size","value":"n=37","value_numeric":37},{"paper_doi":"10.1002/jpn3.70484","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"warning","value":"Incidence estimate of 1/20,000 patient-years is derived from regional (EPIMAD) data extrapolated to the French national pediatric IBD population — generalizability to other countries is uncertain.","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"warning","value":"Small sample size (n=37) limits precision of all subgroup analyses, including remission and relapse rates by treatment.","value_numeric":null},{"paper_doi":"10.1002/jpn3.70484","tag_type":"warning","value":"The specific anti-TNF-α agents used are not named in the abstract; generic and brand tags could not be specified beyond drug class.","value_numeric":null}],"summaries":{"what_studied":"This retrospective French national cohort study described the clinical features and outcomes of pediatric patients with both inflammatory bowel disease (IBD) and chronic nonbacterial osteomyelitis (CNO), enrolled from gastroenterological and rheumatological units between 2000 and 2024, and estimated the incidence of IBD-CNO among pediatric IBD patients.","key_result":"37 pediatric patients were identified (median age 13.5 years); Crohn's disease was most common (25/37). At median 3-year follow-up, 75.7% achieved IBD-CNO remission, with anti-TNF-α therapy associated with the highest remission rate (82.1%, p=0.041). Incidence was estimated at 1 case per 20,000 patient-years among French pediatric IBD.","limitations":"Retrospective design with potential underreporting due to low clinical awareness; reliance on voluntary case reports from participating units may miss cases; incidence estimate depends on EPIMAD regional cohort data extrapolated nationally.","practice_takeaway":"Order whole-body MRI in IBD children with chronic bone pain to screen for CNO. Anti-TNF-α monotherapy appears effective for both conditions and may prevent bone complications; multidisciplinary involvement of rheumatology and dermatology is recommended."}},{"doi":"10.1038/s41433-026-04460-x","pmid":"42215634","title":"Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04460-x","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-01T13:39:30.001Z","updated_at":"2026-06-01T13:39:30.001Z","tags":[{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"condition","value":"Juvenile Idiopathic Arthritis-Associated Uveitis","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"condition","value":"Paediatric Chronic Anterior Uveitis","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"sample_size","value":"n=15","value_numeric":15},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"warning","value":"Sample size of 15 is very small; all subgroup analyses and statistical comparisons are substantially underpowered — results should be treated as hypothesis-generating only.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"warning","value":"Serum adalimumab levels were measured at random time points, not standardised trough levels, which limits direct comparison with published therapeutic drug monitoring thresholds.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"warning","value":"The brand tag 'Humira' is inferred as the most common adalimumab brand in UK NHS practice; the paper does not specify the brand used.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04460-x","tag_type":"warning","value":"Weekly adalimumab remains off-label for uveitis in this population; the study reflects real-world UK tertiary practice and may not generalise to other healthcare settings.","value_numeric":null}],"summaries":{"what_studied":"Retrospective review of 15 children (mean age 11 years, range 3–17) with refractory non-infectious paediatric chronic anterior uveitis at two UK tertiary centres, evaluating escalation from standard biweekly to weekly adalimumab, including the predictive value of serum drug levels and anti-adalimumab antibodies (AAA) over a mean follow-up of 230 days.","key_result":"67% (10/15) achieved treatment success (≤0.5+ anterior chamber cells, <2 steroid drops/day) at 3 months. Median serum adalimumab rose from 10.1 mg/L pre-escalation to 18.1 mg/L post-escalation. AAAs were present in 47% pre-escalation and fell to 13% post-escalation, with 57% of AAA-positive patients seroconverting. Visual acuity improved or stayed stable in 93% of affected eyes. No serious adverse events occurred.","limitations":"- Very small sample (n=15); all findings are underpowered and statistically non-significant.\n- Serum ADA levels were random (not trough), limiting pharmacokinetic comparability and potentially inflating post-escalation concentrations.\n- Retrospective single-arm design with variable follow-up duration and no control group.","practice_takeaway":"Weekly adalimumab appears safe and effective as a next step for children with refractory uveitis failing biweekly dosing, including those with detectable anti-drug antibodies. However, neither serum drug level nor antibody status reliably predicted response, so clinical judgement rather than biomarker thresholds should guide escalation decisions until larger prospective data are available."}},{"doi":"10.1007/s13555-026-01761-7","pmid":"42068460","title":"A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-05-02T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01761-7","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-10T13:20:36.620Z","updated_at":"2026-05-10T13:20:36.620Z","tags":[{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Otezla","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Sotyktu","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"apremilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"deucravacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Conventional Synthetic DMARD","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"NSAID","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TYK2 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Corresponding author (Tsen-Fang Tsai) has disclosed extensive consultant relationships with manufacturers of many drugs discussed in the review.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Level of evidence assigned as 5 (narrative review/expert opinion) due to absence of PRISMA methodology, risk-of-bias tools, or meta-analytic synthesis, even though individual cited studies range from Level 1 to Level 5.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Several drug-AD associations cited are from studies in rheumatoid arthritis populations, not specifically psoriasis patients; generalizability to psoriatic disease may be limited.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"This is a narrative review without formal systematic methods; findings are hypothesis-generating and subject to selection bias in included studies.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examined whether systemic drugs used for psoriatic disease (NSAIDs, methotrexate, cyclosporin, retinoids, PDE4 inhibitors, JAK inhibitors, TYK2 inhibitors, and biologics targeting TNF-α, IL-12/23, IL-17, and IL-23) influence the risk or progression of Alzheimer's disease (AD), using AD as a model for dementia. Literature from PubMed (2015–2025) was synthesized across preclinical, observational, and RCT-level evidence.","key_result":"Most preclinical and observational data suggest antipsoriatic therapies may reduce AD risk. The strongest clinical signal comes from a propensity score–matched cohort (n=1,766) showing biologic therapy for psoriasis was associated with a **53% lower risk of incident dementia** vs. conventional systemic therapy alone. In a large EHR-based study (56 million records), TNF inhibitors (etanercept, adalimumab, infliximab) were linked to markedly reduced AD odds (ORs 0.34, 0.28, and 0.52, respectively; all P<0.0001). However, several large observational studies found the psoriasis–dementia association attenuated or disappeared after adjusting for comorbidities.","limitations":"- Narrative (not systematic) review with no PRISMA flow, risk-of-bias assessment, or quantitative synthesis, limiting reproducibility.\n- Most mechanistic evidence comes from preclinical models (Level 5), with very few adequately powered RCTs in humans.\n- Residual confounding by disease severity, metabolic comorbidities, and medication use cannot be excluded in observational studies.","practice_takeaway":"For older patients with psoriasis, consider early cognitive screening, as shared inflammatory mechanisms may raise dementia risk—especially in those with metabolic comorbidities. Biologic therapy, particularly TNF inhibitors, shows the most consistent signal for possible neuroprotection, but current evidence is hypothesis-generating and should not yet change prescribing solely for dementia prevention."}},{"doi":"10.1182/bloodadvances.2025018853","pmid":"41961998","title":"Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-04-10T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025018853","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-03T13:39:00.566Z","updated_at":"2026-07-03T13:39:00.566Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"brand","value":"Carvykti","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"brand","value":"Vedolizumab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"condition","value":"Immune Effector Cell-Associated Enterocolitis","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"generic","value":"ciltacabtagene autoleucel","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"modality","value":"Anti-Integrin Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"sample_size","value":"n=229","value_numeric":229},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"study_design","value":"Retrospective Case Series","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"warning","value":"GI coinfection was present in 5 of 9 cases and appeared to predict non-response to biologic therapy, but the small numbers preclude firm conclusions about causality.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"warning","value":"Only 9 IEC-EC cases were identified, making multivariable risk factor estimates (especially wide confidence intervals) highly uncertain and difficult to generalize.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"warning","value":"The distinction between IEC-EC and T-cell lymphoproliferative disorder (T-LPD) is not yet fully standardized; 2 of 9 cases showed T-LPD patterns, which may have different optimal management.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018853","tag_type":"warning","value":"Vedolizumab brand tag added for clarity, though 'Entyvio' is the marketed brand name; 'Vedolizumab' used here as noted in the paper.","value_numeric":null}],"summaries":{"what_studied":"This retrospective case series examined the incidence, clinical features, risk factors, and management outcomes of immune effector cell–associated enterocolitis (IEC-EC) in 229 consecutive patients who received cilta-cel (ciltacabtagene autoleucel) for relapsed/refractory multiple myeloma at three Mayo Clinic sites between February 2022 and November 2024.","key_result":"IEC-EC occurred in 9 of 229 patients (3.9%), presenting as persistent grade ≥3 nonbloody diarrhea at a median of 85 days post-infusion. First-line corticosteroids and supportive care produced no durable responses. Biologic therapy yielded durable responses in 3 of 5 patients who received it (2/2 with vedolizumab; 1/3 with infliximab); all 3 responders had no concurrent GI infection. Independent risk factors were IMS/IMWG high-risk disease (OR 6.1; 95% CI, 1.2–30), prolonged CRS ≥3 days, and antecedent delayed neurotoxicity (OR 10.6; 95% CI, 2.0–69.3).","limitations":"- Very small case series (n=9 IEC-EC) limits statistical power and generalizability.\n- Retrospective design with missing data and likely selection bias toward more severe cases.\n- Single-institution (multi-site) experience may not reflect treatment-access disparities elsewhere.","practice_takeaway":"In cilta-cel recipients with persistent grade ≥2 diarrhea—especially those with prior delayed neurotoxicity or high-risk myeloma—pursue early endoscopy with duodenal biopsy (highest histopathological yield) and rule out GI infection. If first-line corticosteroids fail within one week, escalate promptly to biologic therapy (vedolizumab or infliximab), as prolonged steroid courses appear ineffective and durable responses are tied to early biologic use in patients without concurrent GI infection."}},{"doi":"10.1016/j.jaad.2026.01.043","pmid":"41616932","title":"Skin and soft tissue infections in pediatric patients with inflammatory bowel disease treated with tumor necrosis factor-α inhibitors","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-01-29T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.01.043","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-30T13:22:42.824Z","updated_at":"2026-05-30T13:22:42.824Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"condition","value":"Skin and Soft Tissue Infections","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"warning","value":"Impact flag 'safety_signal' is inferred from the topic (infection risk with immunosuppression in children) but may not reflect the authors' conclusions.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"warning","value":"Level of evidence is estimated as 4 (case series or retrospective cohort) based on typical study designs for this research question, but cannot be confirmed without full text.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.01.043","tag_type":"warning","value":"Only the paper citation metadata was provided — no abstract, methods, results, or full text were available. Key fields such as key_result, sample_size, sex, and study_design could not be reliably extracted and have been omitted or estimated conservatively.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the incidence and characteristics of skin and soft tissue infections (SSTIs) in pediatric patients with inflammatory bowel disease (IBD) who were treated with tumor necrosis factor-α (TNF-α) inhibitors.","limitations":"The paper abstract provides insufficient detail to extract specific outcome data, sample size, or comparator arms.","practice_takeaway":"Clinicians managing pediatric IBD patients on TNF-α inhibitors should maintain heightened vigilance for skin and soft tissue infections as a potential treatment-related complication."}},{"doi":"10.1001/jamadermatol.2025.2972","pmid":"40900466","title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-09-03T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2972","source_score":13,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-21","doi":"10.1001/jamadermatol.2025.2972","days":"7","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"13","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2972","title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.","journal":"JAMA dermatology","methods":"","results":"Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change.","abstract":"$30","keywords":[],"pubmed_id":"40900466","conclusions":"","publication_date":"2025-09-03T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2972","URL":"https://doi.org/10.1001/jamadermatol.2025.2972","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2838219/jamadermatology_raby_2025_oi_250041_1762976601.59148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1107","type":"journal-article","issue":"11","score":1,"title":["Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events"],"author":[{"given":"Maxime","family":"Raby","sequence":"first","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]},{"given":"Frederic","family":"Balusson","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes Hospital, France"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes Hospital, France"}]},{"given":"Marion","family":"Gundelwein","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]},{"given":"Florence","family":"Poizeau","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]}],"issued":{"date-parts":[[2025,11,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-09-03T15:00:28Z","timestamp":1756911628000,"date-parts":[[2025,9,3]]},"indexed":{"date-time":"2025-11-19T16:04:21Z","timestamp":1763568261864,"date-parts":[[2025,11,19]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2838219"}},"subtitle":[],"deposited":{"date-time":"2025-11-19T16:00:39Z","timestamp":1763568039000,"date-parts":[[2025,11,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1093/eurheartj/ehr285","key":"doi250041r1","year":"2012","issue":"16","author":"Ahlehoff","volume":"33","first-page":"2054","unstructured":null,"article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-020-01346-6","key":"doi250041r2","year":"2020","issue":"5","author":"Masson","volume":"37","first-page":"2017","unstructured":null,"article-title":"Psoriasis and cardiovascular risk: a comprehensive review.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/ehp567","key":"doi250041r3","year":"2010","issue":"8","author":"Mehta","volume":"31","first-page":"1000","unstructured":null,"article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2009.446","key":"doi250041r4","year":"2010","issue":"4","author":"Stern","volume":"130","first-page":"917","unstructured":null,"article-title":"Psoriasis is not a useful independent risk factor for cardiovascular disease.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamacardio.2024.2859","key":"doi250041r5","year":"2024","issue":"11","author":"Ramessur","volume":"9","first-page":"1009","unstructured":null,"article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis.","journal-title":"JAMA Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.4433","key":"doi250041r6","year":"2024","issue":"1","author":"Svedbom","volume":"161","first-page":"81","unstructured":null,"article-title":"Skin inflammation, systemic inflammation, and cardiovascular disease in psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2018.07.004","key":"doi250041r7","year":"2019","issue":"1","author":"Kim","volume":"37","first-page":"29","unstructured":null,"article-title":"Biologics and psoriasis: the beat goes on.","journal-title":"Dermatol Clin","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/ket303","key":"doi250041r8","year":"2005","issue":"7","author":"Jacobsson","volume":"32","first-page":"1213","unstructured":null,"article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.","journal-title":"J Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.110.214585","key":"doi250041r9","year":"2011","issue":"3","author":"Di Minno","volume":"31","first-page":"705","unstructured":null,"article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-a blockers and traditional disease-modifying antirheumatic drugs.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2796.2012.02593.x","key":"doi250041r10","year":"2013","issue":"2","author":"Ahlehoff","volume":"273","first-page":"197","unstructured":null,"article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.","journal-title":"J Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2012.2502","key":"doi250041r11","year":"2012","issue":"11","author":"Wu","volume":"148","first-page":"1244","unstructured":null,"article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2011.10525.x","key":"doi250041r12","year":"2011","issue":"5","author":"Abuabara","volume":"165","first-page":"1066","unstructured":null,"article-title":"The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.0001","key":"doi250041r13","year":"2019","issue":"6","author":"Lee","volume":"155","first-page":"700","unstructured":null,"article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18964","key":"doi250041r14","year":"2023","issue":"7","author":"Salahuddin","volume":"37","first-page":"e862","unstructured":null,"article-title":"Biologic therapy for psoriasis is associated with reduced risk of death: Insights from the VA clinical assessment, reporting and tracking program.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.2147/PTT.S328575","key":"doi250041r15","year":"2022","issue":null,"author":"Al-Janabi","volume":"12","first-page":"1","unstructured":null,"article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management.","journal-title":"Psoriasis (Auckl)","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250041r16","year":"2015","issue":"7","author":"Papp","volume":"14","first-page":"706","unstructured":null,"article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1038/jid.2011.304","key":"doi250041r17","year":"2012","issue":"2","author":"Gordon","volume":"132","first-page":"304","unstructured":null,"article-title":"A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate to severe psoriasis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(23)00120-0","key":"doi250041r18","year":"2023","issue":"9","author":"Papp","volume":"5","first-page":"e542","unstructured":null,"article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.","journal-title":"Lancet Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2011.1211","key":"doi250041r19","year":"2011","issue":"8","author":"Ryan","volume":"306","first-page":"864","unstructured":null,"article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.12126","key":"doi250041r20","year":"2013","issue":"12","author":"Tzellos","volume":"27","first-page":"1586","unstructured":null,"article-title":"Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1505066","key":"doi250041r21","year":"2015","issue":"26","author":"Baeten","volume":"373","first-page":"2534","unstructured":null,"article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1412679","key":"doi250041r22","year":"2015","issue":"14","author":"Mease","volume":"373","first-page":"1329","unstructured":null,"article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad039","key":"doi250041r23","year":"2023","issue":"6","author":"Egeberg","volume":"188","first-page":"793","unstructured":null,"article-title":"Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bcp.15581","key":"doi250041r24","year":"2023","issue":"8","author":"Woods","volume":"89","first-page":"2386","unstructured":null,"article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).","journal-title":"Br J Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijcard.2024.131819","key":"doi250041r25","year":"2024","issue":null,"author":"Al-Yafeai","volume":"402","first-page":null,"unstructured":null,"article-title":"Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS).","journal-title":"Int J Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamacardio.2024.2868","key":"doi250041r26","year":"2024","issue":"11","author":"Garshick","volume":"9","first-page":"961","unstructured":null,"article-title":"Psoriasis and atherosclerotic CV disease—risk factor or risk marker?","journal-title":"JAMA Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.2977","key":"doi250041r27","year":"2020","issue":"11","author":"Poizeau","volume":"156","first-page":"1208","unstructured":null,"article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/keab522","key":"doi250041r28","year":"2022","issue":"4","author":"Pina Vegas","volume":"61","first-page":"1589","unstructured":null,"article-title":"Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2019.03096","key":"doi250041r29","year":"2020","issue":null,"author":"von Stebut","volume":"10","first-page":"3096","unstructured":null,"article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1093/cvr/cvz009","key":"doi250041r30","year":"2019","issue":"4","author":"Elnabawi","volume":"115","first-page":"721","unstructured":null,"article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.","journal-title":"Cardiovasc Res","doi-asserted-by":"publisher"},{"DOI":"10.3390/biomedicines11020318","key":"doi250041r31","year":"2023","issue":"2","author":"Tsiogka","volume":"11","first-page":"318","unstructured":null,"article-title":"The impact of treatment with IL-17/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis: a systematic review.","journal-title":"Biomedicines","doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/ehs263","key":"doi250041r32","year":"2013","issue":"8","author":"Simon","volume":"34","first-page":"570","unstructured":null,"article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.114.303567","key":"doi250041r33","year":"2015","issue":"2","author":"Taleb","volume":"35","first-page":"258","unstructured":null,"article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCRESAHA.122.320263","key":"doi250041r34","year":"2022","issue":"12","author":"Gisterå","volume":"130","first-page":"1869","unstructured":null,"article-title":"Animal models of atherosclerosis-supportive notes and tricks of the trade.","journal-title":"Circ Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.atherosclerosis.2021.09.024","key":"doi250041r35","year":"2021","issue":null,"author":"Lutgens","volume":"335","first-page":"98","unstructured":null,"article-title":"Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies.","journal-title":"Atherosclerosis","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.4233","key":"doi250041r36","year":"2017","issue":"8","author":"Bezin","volume":"26","first-page":"954","unstructured":null,"article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12874-021-01440-5","key":"doi250041r37","year":"2021","issue":"1","author":"Bosco","volume":"21","first-page":"241","unstructured":null,"article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","journal-title":"BMC Med Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.therap.2023.01.009","key":"doi250041r38","year":"2023","issue":"6","author":"de Germay","volume":"78","first-page":"679","unstructured":null,"article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice.","journal-title":"Therapie","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16566","key":"doi250041r39","year":"2021","issue":"2","author":"Grodner","volume":"35","first-page":"411","unstructured":null,"article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000438859","key":"doi250041r40","year":"2015","issue":"1-2","author":"Giroud","volume":"74","first-page":"92","unstructured":null,"article-title":"Positive predictive value of French hospitalization discharge codes for stroke and transient ischemic attack.","journal-title":"Eur Neurol","doi-asserted-by":"publisher"},{"DOI":"10.1097/00001648-199505000-00010","key":"doi250041r41","year":"1995","issue":"3","author":"Suissa","volume":"6","first-page":"248","unstructured":null,"article-title":"The case–time-control design.","journal-title":"Epidemiology","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJM199312023292301","key":"doi250041r42","year":"1993","issue":"23","author":"Mittleman","volume":"329","first-page":"1677","unstructured":null,"article-title":"Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(97)11084-4","key":"doi250041r43","year":"1998","issue":"9114","author":"Meier","volume":"351","first-page":"1467","unstructured":null,"article-title":"Acute respiratory-tract infections and risk of first-time acute myocardial infarction.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.1996.03530420033032","key":"doi250041r44","year":"1996","issue":"18","author":"Muller","volume":"275","first-page":"1405","unstructured":null,"article-title":"Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1093/oxfordjournals.aje.a115853","key":"doi250041r45","year":"1991","issue":"2","author":"Maclure","volume":"133","first-page":"144","unstructured":null,"article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events.","journal-title":"Am J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1093/aje/kwab110","key":"doi250041r46","year":"2021","issue":"10","author":"Hallas","volume":"190","first-page":"2181","unstructured":null,"article-title":"The use of active comparators in self-controlled designs.","journal-title":"Am J Epidemiol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250041r47","year":"2015","issue":"1/2","author":"Hashemi-Nazari","volume":"1","first-page":"59","unstructured":null,"article-title":"Case-crossover and case–time-control studies: concepts, design, and analysis.","journal-title":"J Biostat Epidemiol","doi-asserted-by":null},{"DOI":"10.1093/ije/dyu081","key":"doi250041r48","year":"2014","issue":"5","author":"Mittleman","volume":"43","first-page":"1645","unstructured":null,"article-title":"Exchangeability in the case-crossover design.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2021-222027","key":"doi250041r49","year":"2022","issue":"7","author":"Deodhar","volume":"81","first-page":"944","unstructured":null,"article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.111.229997","key":"doi250041r50","year":"2012","issue":"2","author":"Danzaki","volume":"32","first-page":"273","unstructured":null,"article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16273","key":"doi250041r51","year":"2020","issue":"8","author":"Egeberg","volume":"34","first-page":"1695","unstructured":null,"article-title":"The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13075-023-03257-7","key":"doi250041r52","year":"2024","issue":"1","author":"Deodhar","volume":"26","first-page":"49","unstructured":null,"article-title":"Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.","journal-title":"Arthritis Res Ther","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v102.563","key":"doi250041r53","year":"2022","issue":null,"author":"Gottlieb","volume":"102","first-page":null,"unstructured":null,"article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13075-019-1882-2","key":"doi250041r54","year":"2019","issue":"1","author":"Deodhar","volume":"21","first-page":"111","unstructured":null,"article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.","journal-title":"Arthritis Res Ther","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20128","key":"doi250041r55","year":"2025","issue":"3","author":"Poizeau","volume":"39","first-page":"447","unstructured":null,"article-title":"Biologics targeting interleukin (IL)-23 and the risk of cardiovascular events: where are we?","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.publhealth.21.1.193","key":"doi250041r56","year":"2000","issue":null,"author":"Maclure","volume":"21","first-page":"193","unstructured":null,"article-title":"Should we use a case-crossover design?","journal-title":"Annu Rev Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.5031","key":"doi250041r57","year":"2020","issue":"9","author":"Bykov","volume":"29","first-page":"1079","unstructured":null,"article-title":"Bias in case-crossover studies of medications due to persistent use: a simulation study.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.5490","key":"doi250041r58","year":"2022","issue":"10","author":"Rasmussen","volume":"31","first-page":"1015","unstructured":null,"article-title":"Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2024.1353893","key":"doi250041r59","year":"2024","issue":null,"author":"Zhang","volume":"11","first-page":null,"unstructured":null,"article-title":"Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials.","journal-title":"Front Med (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.7759/cureus.60980","key":"doi250041r60","year":"2024","issue":"5","author":"Ni","volume":"16","first-page":null,"unstructured":null,"article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"Cureus","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2020.01.025","key":"doi250041r61","year":"2020","issue":"9","author":"Gelfand","volume":"140","first-page":"1784","unstructured":null,"article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S).","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.02.074","key":"doi250041r62","year":"2018","issue":"1","author":"Egeberg","volume":"79","first-page":"104","unstructured":null,"article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40744-022-00434-z","key":"doi250041r63","year":"2022","issue":"3","author":"Merola","volume":"9","first-page":"935","unstructured":null,"article-title":"Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications.","journal-title":"Rheumatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.10.042","key":"doi250041r64","year":"2019","issue":"5","author":"von Stebut","volume":"139","first-page":"1054","unstructured":null,"article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,11,1]]},"reference-count":64,"published-online":null,"references-count":64,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2972","is_oa":false,"title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events","updated":"2025-09-04T02:50:00+00:00","published_date":"2025-09-03","best_oa_location":null}},"created_at":"2025-11-23T07:03:49.856Z","updated_at":"2025-11-28T07:01:22.464Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Ankylosing Spondylitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Juvenile Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"sample_size","value":"n=34,241","value_numeric":34241},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"study_design","value":"Case-Time-Control Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Abstract reports odds ratios without absolute event rates by exposure group.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Design labeled as case–time–control; classification may be unfamiliar to some readers.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Only early (3–6 month) risk windows were evaluated; longer-term risk remains uncertain.","value_numeric":null}],"summaries":{"what_studied":"A national case–time–control study of the French health insurance database (2016–2021) assessed whether initiating IL‑17(R)A inhibitors (secukinumab, ixekizumab, brodalumab) triggers major adverse cardiovascular events (MACEs) within 6 months, using TNF‑α inhibitors (adalimumab, etanercept) as an active comparator. Among 34,241 IL‑17(R)A recipients, 381 MACEs were analyzed; risk and reference windows were the 6 months before the MACE and the preceding 6 months.","key_result":"Initiation of IL‑17(R)A inhibitors was not significantly associated with MACEs (OR 1.25, 95% CI 0.75–2.08); TNF‑α inhibitor initiation also showed no association (OR 0.90, 95% CI 0.65–1.24). Compared with TNF‑α inhibitors, IL‑17(R)A initiation had an OR of 1.40 (95% CI 0.77–2.54) over 6 months, with similar findings across cardiovascular risk strata (P for homogeneity = .29) and unchanged results in sensitivity analyses (broader MACE definition; 3‑month risk window).","limitations":"Only early risk windows (3–6 months) were evaluated, so longer‑term risk was not assessed. Precision was limited by 381 MACEs, yielding wide confidence intervals that do not exclude a modest risk increase.","practice_takeaway":"In this large real‑world analysis, starting an IL‑17(R)A inhibitor did not show a significant increase in 6‑month MACEs versus TNF‑α inhibitors, across cardiovascular risk levels. Continue standard cardiovascular risk management; a small increase in early events cannot be ruled out."}}],"initialOffset":8,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"TNF-Alpha Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"TNF-Alpha Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"TNF-Alpha Inhibitor"}}}]]

Papers